All News

The development of 2 panels measuring levels of tumor-associated autoantibodies (TAAbs) has promise for predicting therapeutic response and adverse events for patients with advanced non–small cell lung cancer (NSCLC) after immune checkpoint inhibitor–based treatment.

Abstract findings presented at the 2022 American Academy of Dermatology Annual Meeting showed that patients with moderate to severe psoriasis achieved improvement in work-/study-related productivity with tildakizumab vs placebo after only 2 doses.

Findings of a Mendelian randomization analysis showed that greater body mass index as a child and adult and incidence of smoking were associated with an increased risk of psoriasis, whereas having more education was cited as a potential protective factor against development.

HHS updated guidance for states using Medicaid managed care to manage nonmedical needs; anxieties surrounding new variants rise amidst underreported COVID-19 cases in China, which defended its counts; public health campaigns try new strategies to increase trust and promote immunizations.

Investigators writing in BMJ Open called for “a complete restoration of FOURIER trial data.” Amgen, the maker of evolocumab, said it stood by the data.

This study investigated the effects of antimicrobial therapy among patients with non–small cell lung cancer (NSCLC) who received immunotherapy with a checkpoint inhibitor or chemotherapy plus immunotherapy (CIT).

Michael Thompson, president and CEO of the National Alliance of Healthcare Purchaser Coalitions (National Alliance), addressed the current state of health equity strategies in the workplace and how employers can better address inequities in their benefit designs, programs, and policies in the near future.

A study showed that Canadian women living with HIV were less likely to get vitamin D through dairy consumption, but more likely to take vitamin D supplements, compared with women without HIV.

Despite chronic obstructive pulmonary disease (COPD) being associated with poor mental health and depression, most older adults report being free of mental illness or substance abuse, a new study has found.

A Hispanic community health study is the first of its kind to evaluate the prevalence and determinants of e-cigarette use among Hispanic and Latino populations living in the United States.

Dual-regimen abortion pills authorized for pharmacy sale by FDA; health professionals turn a critical eye to US concerns about COVID-19 in China while domestic cases rise here as vaccination rates drop; drug manufacturers are collectively raising prices early this month on medications from autoimmune treatments to shingles vaccines to cancer treatments.

New study findings show that internalized problems such as anxiety and depression were found at higher levels in children and infants who had a diagnosis of spinal muscular atrophy (SMA).

With mixed findings from previous studies focused on atopic dermatitis and the use of cognitive behavioral therapy (CBT) as a treatment modality, investigators modified an existing online CBT intervention to account for the lack of clinical psychologists in the dermatological space.

Approximately 14,280 more US patients with psoriasis were estimated to initiate a biologic in Spring than in other seasons, and over 840 more biologic users switched in Spring than in Winter.

A clinical trial found that the prevalence of age-related macular degeneration (AMD) was not associated with the use of metformin.

The Chinese government warns of backlash for countries requiring COVID-19 testing of travelers from China; monoclonal antibody drugs show some promise against infectious diseases, but costs need to be lower; the role of FDA and Biogen in approving Alzheimer drug Aduhelm is detailed in a scathing Congressional committee report.

Our top coverage from this year’s San Antonio Breast Cancer Symposium (SABCS) included updated data on tamoxifen and trastuzumab deruxtecan, treatments long proven effective in the breast cancer space.

With data collection beginning on January 1, 2023, most health systems are not prepared for CMS’ new glycemia measures, and those that are will likely be floored by the results, according to the chief medical officer at Glytec.

The top 5 most-read rheumatology articles of 2022 covered the topics of management of inflammatory arthritis and new inflammatory protein identification.

The top 5 most-read articles on AJMC.com for 2022 covered COVID-19, the first treatment for repigmentation in vitiligo, migraine care, and vitamin D supplementation for patients with multiple myeloma.

The addition of adalimumab biosimilars to formularies can help accelerate realized savings as the blockbuster drug Humira faces competition from multiple biosimilars, including 1 approved interchangeable biosimilar.

M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, discusses the benefits of de-escalating treatment for patients with multiple myeloma.

The most-read articles in pulmonary arterial hypertension (PAH) for this year ran the gamut of special-interest areas: from treatment costs to pediatric PAH to high-risk patients.

The top 5 most-read content in ophthalmology for 2022 focused on the relationship between aging and visual field reliability, telehealth eye care visits, the link between COVID-19 and dry eye disease, and more.

This year’s top 5 most-viewed videos include topics on eosinophilic esophagitis (EoE), cancer screening awareness, and racial/ethnic and socioeconomic barriers to care.

The American Journal of Managed Care® covered thousands of miles in 2022, virtually and in person, criss-crossing the country and the world to deliver the latest clinical data, trial results, and drug developments.

This year’s most-read articles on dermatology covered the first and only FDA-approved treatment for repigmentation in patients with vitiligo, as well as other therapies for the treatment of acne, hidradenitis suppurativa, and more.

The top 5 pieces of content published on AJMC.com relating to reimbursement issues included 2 on the significance of a California law giving Medicare beneficiaries access to expert oncology care; other articles looked at the work involved in value-based care models and CMS news.

Two abstracts reviewed venetoclax, the first FDA-approved BCL-2 inhibitor in acute myeloid leukemia (AML) and a novel BCL-2 inhibitor to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Patrick Reville, MD, MPH, instructor, Department of Leukemia, MD Anderson Cancer Center, explains the implications of the longer-term follow-up of venetoclax in combination with the chemotherapy regimen cladribine, high-dose cytarabine, idarubicin (CLIA) and how age is a factor when considering chemotherapy options.